2-Bromothiazole → (2-Nitro-4-thiazol-2-yl-phenyl)-carbamic acid tert.-butyl ester
Reaktionsgleichung
[C:1]([O:5][C:6](=[O:30])[NH:7][C:8]1[CH:13]=[CH:12][C:11]([Sn](CCCC)(CCCC)CCCC)=[CH:10][C:9]=1[N+:27]([O-:29])=[O:28])([CH3:4])([CH3:3])[CH3:2].Br[C:32]1[S:33][CH:34]=[CH:35][N:36]=1>>[C:1]([O:5][C:6](=[O:30])[NH:7][C:8]1[CH:13]=[CH:12][C:11]([C:32]2[S:33][CH:34]=[CH:35][N:36]=2)=[CH:10][C:9]=1[N+:27]([O-:29])=[O:28])([CH3:2])([CH3:3])[CH3:4]Komponenten
3
Versuchsvorschrift
Prepared from (2-nitro-4-tributylstannanyl-phenyl)-carbamic acid tert.-butyl ester (Example D2) (1.0 g, 1.9 mmol) and 2-bromothiazole (0.56 mL, 6.27 mmol) according to the general procedure E. Obtained as a yellow solid (160 mg). MS (EI) 321 (M+).
Quellen und Nachweise
- ORD-Eintrag
- ord-cb5c63288dcd47c4b09ae25678bc1549
- Quelldatensatz
- uspto-grants-2006_12